Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Biochem Pharmacol. 2021 Feb 10;186:114462. doi: 10.1016/j.bcp.2021.114462

Table 3.

Effects of flavonoids and CDK9 inhibitors on CDK9 activity, Tat-dependent transactivation, and cellular HDAC activity.

Compound CDK9 inhibition
IC50 (μM)		 Tat-dependent
transactivation
EC50 (μM)		 HDAC Inhibition
IC50 (μM)
Chrysin 0.021 ± 0.010 7.1 ± 1.0 24.0 ± 4.8
Apigenin 0.21 ± 0.10 8.5 ± 0.9 47.2 ± 6.7
Luteolin 0.072 ± 0.030 22.2 ± 5.0 > 90
L7G 6.9 ± 3.9 > 30 > 90
Naringenin > 30 > 30 88.7 ± 32.1
Flavopiridol 0.0014 ± 0.0008 0.050 ± 0.003 > 1
Atuveciclib 0.035 ± 0.020 5.8 ± 0.4 > 90